DYV800 Topical Therapy Targets Tumor Acidity to Restore T-Cell Activity in Preclinical Bladder Cancer Study

Bladder cancer remains one of the most common urologic malignancies worldwide, with significant challenges in treatment due to its aggressive nature and frequent recurrence. Recent preclinical research has spotlighted a novel approach: DYV800, a transdermal cream developed by Dyve Biosciences in collaboration with researchers at the H. Lee Moffitt Cancer Center and the University of South Florida. This therapy targets the acidic tumor microenvironment—a key barrier to effective immunotherapy—by raising intratumoral pH, thereby restoring T-cell function and slowing tumor growth in mouse models.

The study, published on March 13, 2026, in Frontiers in Immunology, demonstrates how tumor acidity (typically pH 6.2–6.8 in solid tumors compared to physiological pH 7.4) suppresses immune responses. Acidic conditions impair T-cell proliferation, migration, cytokine production, and antigen recognition, contributing to immunotherapy resistance. DYV800, a sodium bicarbonate-based formulation, addresses this by delivering bicarbonate systemically through the skin, bypassing gastrointestinal issues associated with oral buffers.

Understanding Tumor Acidity and Its Role in Bladder Cancer Progression

The tumor microenvironment (TME) in bladder cancer is notoriously hostile, characterized by low extracellular pH due to excessive lactic acid production from glycolysis (the Warburg effect). This acidity not only promotes tumor invasion and metastasis but also acts as an 'upstream immune checkpoint,' inhibiting CD8+ T cells before traditional checkpoints like PD-1/PD-L1 come into play. In preclinical assays, T cells cultured at pH 6.6 showed 3.5-fold reduced proliferation, diminished migration toward chemokines like CXCL10, and lower production of key cytokines such as IFN-γ, TNF-α, and IL-2. RNA sequencing revealed downregulated pathways for glycolysis and cell cycle progression, with G0/G1 arrest in 99% of acidic-exposed cells versus 30% at neutral pH.

Globally, bladder cancer accounted for approximately 614,000 new cases and 220,000 deaths in 2022, with projections stable but persistent in high-income regions like the US, where 84,530 diagnoses and 17,870 deaths are expected in 2026. In the US, incidence rates are 18.0 per 100,000, with higher mortality in advanced stages due to immune evasion mechanisms like acidity. For researchers and students in oncology at institutions like Moffitt and USF, understanding these dynamics is crucial for developing next-generation therapies.

How DYV800 Works: Transdermal Delivery Revolutionizes pH Modulation

DYV800 is applied topically as a cream, allowing bicarbonate to penetrate the skin and circulate systemically. Unlike oral sodium bicarbonate, which requires high doses causing GI distress, DYV800 achieves sustained pH elevation without these side effects. In mouse models, a single application raised urine pH for up to 10 hours and intratumoral pH within 4-6 hours, confirmed via advanced CEST-MRI imaging that maps spatial pH distribution.

Chemical Exchange Saturation Transfer Magnetic Resonance Imaging (CEST-MRI) provided precise, non-invasive pH measurements, showing treated tumors shifting toward neutral pH. This systemic effect was evident even when cream was applied to the opposite flank from the tumor, highlighting broad applicability for metastatic disease. For academic researchers, this transdermal platform offers a model for non-invasive TME modulation, potentially integrable with ongoing immunotherapy trials.Read the full study here.

Preclinical Methods: Rigorous Mouse Models Mimic Human Bladder Cancer

The study utilized the MB49OVA syngeneic mouse model of bladder cancer, involving subcutaneous and orthotopic implantation in C57BL/6 mice. Treatments began 24 hours or 7 days post-inoculation, with 100 μL DYV800 applied twice daily. Tumor growth was tracked via calipers, ultrasound, and weight; survival via Kaplan-Meier; immune profiles via flow cytometry on tumor digests; pH via CEST-MRI and urine strips. Controls included vehicle and oral bicarbonate for comparison. T-cell functional assays used OT-I and pmel transgenic mice, with RNA-seq on Illumina NovaSeq analyzed via DESeq2 and Ingenuity Pathway Analysis.

• Subcutaneous tumors: Reduced growth area, weight (0.18g vs. 0.55g control, p<0.001), prolonged survival (p<0.001).
• Orthotopic: Decreased bladder tumor volume over 24 days (p<0.05 to <0.001).
• NSG immunodeficient mice: No effect, confirming T-cell dependence.

Key Results: Restored T-Cell Activity and Reduced Tumor Burden

Treated mice exhibited significantly lower tumor burden and higher survival. Flow cytometry revealed increased antigen-specific CD8+ T cells (OVA-tetramer+), elevated effector markers (4-1BB, IFN-γ, TNF-α), and reduced exhaustion (lower PD-1/LAG3). No changes in T-cell proportions, but enhanced functionality. Spatial pH maps (Figure 3C-D in paper) illustrated uniform alkalization. These findings build on 2023 AACR data showing pH modulation in melanoma models, now extended to bladder cancer with antitumor efficacy.

Statistically, chronic DYV800 halved tumor weights and doubled median survival in subcutaneous models.

Implications for Immunotherapy: Overcoming Resistance in Solid Tumors

Acidity precedes PD-1 blockade in suppressing immunity, making pH modulation a synergistic strategy. DYV800's ability to boost CD8+ responses suggests combination potential with checkpoint inhibitors or BCG therapy for non-muscle-invasive bladder cancer. Broader implications for acidic tumors like pancreatic or breast cancer. At USF and Moffitt, this aligns with immunology programs training next-gen researchers.ACS Cancer Facts 2026 highlights bladder cancer's recurrence risk, underscoring need for novel TME-targeted therapies.

Researchers and Institutions Driving Innovation

Lead author Oluwaseyi Oluwatola (Moffitt/USF PhD candidate) conducted functional assays; Shari Pilon-Thomas, PhD (Moffitt CIIRC Co-Director), oversaw immunology; Ryan Beal, PhD (Dyve CEO), developed formulation. Contributors from Moffitt's Tumor Microenvironment, Integrated Mathematical Oncology departments, and USF's Molecular Medicine. This public-private-academic partnership exemplifies translational research.

Moffitt, NCI-designated comprehensive cancer center, integrates with USF Morsani College of Medicine, fostering student training in preclinical models and imaging.

Challenges and Future Directions: From Bench to Bedside

While promising, translation requires phase 1 trials (planned 2026 via Moffitt alliance) to assess safety, dosing, human pH effects. Challenges: confirming systemic delivery in humans, optimizing combinations. Ongoing five-year collaboration will explore other tumors. For higher ed, this highlights transdermal tech's potential in pharma curricula.

Broader Impact on Cancer Research and Education

DYV800 advances TME-targeted therapies, inspiring curricula in tumor immunology at USF/Moffitt. Statistics show immunotherapy response rates ~20-30% in bladder cancer; pH modulation could boost this. Students can explore CEST-MRI, syngeneic models via lab rotations. Future: clinical integration, patents, jobs in oncology biotech.Dyve-Moffitt Press Release.

Stakeholder Perspectives and Ethical Considerations

Pilon-Thomas notes: 'Tumor acidity is a fundamental barrier to immune function.' Beal emphasizes non-invasive delivery. Ethically, preclinical success must translate safely; equity in access for bladder cancer patients globally. Academic discourse focuses on combo trials, biomarker development.

Comparative Therapies and Competitive Landscape

Oral bicarbonate showed limited pH change; DYV800 superior. Vs. proton pump inhibitors or buffers, transdermal avoids systemic alkalosis. Complements CAR-T, BCG. No direct competitors in topical pH modulation.

Photo by Claudio Schwarz on Unsplash

• DYV800: Systemic, tolerable, preclinical antitumor.
• Oral NaHCO3: GI issues, modest pH shift.
• IV buffers: Invasive.

Outlook: Transforming Bladder Cancer Treatment

With first-in-human trials imminent, DYV800 could redefine TME modulation, enhancing immunotherapy for 84k+ annual US cases. For universities, it underscores interdisciplinary research (immunology, math modeling, imaging). Promising horizon for patients, researchers, students.